Evidence map›Paper›PMID 42439968›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Should supportive care be started before initiating cancer treatment?

Utae Katsushima, Eisuke Ochi, Yuta Yamanaka, Takuya Fukushima, Jiro Nakano, Keigo Araki, Mai Kitagawa, Natsuno Makihara, Kazuki Fujii, Yutaro Nagata and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Utae KatsushimaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan. katsushima.uta@kmu.ac.jp.ORCID http://orcid.org/0009-0005-1314-5270
Eisuke OchiGraduate School of Sports and Health Studies, Faculty of Bioscience and Applied Chemistry, Hosei University, 2-17-1 Fujimi, Chiyoda-Ku, Tokyo, 102-8160, Japan.
Yuta YamanakaFaculty of Rehabilitation, Kansai Medical University, 18-89 Uyamahigashi-Cho, Hirakata-Shi, Osaka, 573-1136, Japan.
Takuya FukushimaFaculty of Rehabilitation, Kansai Medical University, 18-89 Uyamahigashi-Cho, Hirakata-Shi, Osaka, 573-1136, Japan.
Jiro NakanoFaculty of Rehabilitation, Kansai Medical University, 18-89 Uyamahigashi-Cho, Hirakata-Shi, Osaka, 573-1136, Japan.
Keigo ArakiKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Mai KitagawaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Natsuno MakiharaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Kazuki FujiiKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Yutaro NagataKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Kentaro NakanishiKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Yuta OkazakiKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Kiyori YoshidaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Tatsuki IkomaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Kahori NakahamaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Yuki TakeyasuKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Satoshi IkedaKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Takayasu KurataKansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis comment proposes that the diagnostic waiting period (DWP), defined as the interval from the first specialist visit to anticancer treatment initiation, should be recognized as an opportunity for early supportive care in patients with advanced lung cancer.

methodsWe discuss the clinical rationale for initiating low-burden supportive care at the first specialist visit, drawing on prior observations of clinical deterioration before treatment initiation and feasibility data from a home-based exercise program during the DWP.

resultsThe DWP is often necessary for imaging, tissue sampling, staging, molecular testing, and treatment planning, but patients may experience anxiety, inactivity, anorexia, weight loss, and functional decline during this period. A first-visit supportive care model could include patient education, safe physical activity guidance, nutritional screening, symptom assessment, and timely referral to rehabilitation, dietetic, nursing, or palliative care services.

conclusionReframing the DWP from passive waiting to active preparation may help preserve physical reserve, confidence, and treatment readiness before systemic therapy. Future studies should evaluate which patients should be prioritized, which interventions are most useful, and which outcomes best capture the value of this early supportive care approach.

Indexed as

Lung NeoplasmsPalliative CareHumansTime FactorsTreatment Delay

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.